Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Do you recall where this message thread started, with you arguing that Erdogan was the best possible outcome of the election?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=141610426
Now Erdogan has lifted the state of emergency and assumed greater Presidential powers, just as has been anticipated through this whole process....and now you are concerned about Erdogan?
I still don't see him taking any action that will be a direct threat to VLE and Statoil.....he is still interested in trying to meet the requirements to join the EU....and pissing off Norway would not be a good move.
VLE.to: A couple new blog posts from Malcolm Shaw at Hydra Capital discussing the macro and micro aspects of this investment, an admitted "frothing-at-the-mouth bull", but one with a Masters in Geology and a respectable resume of a successful resource investor:
http://hydracapital.ca/hydra-blog.html
VLE.to: I wish I had been more patient in my buying too, I took my initial position during the run the morning the reserve report was issued, then I averaged down a few weeks ago. I have some dry powder waiting to see the production results from Yam-1. When we get to see those Yam-1 results, one will need to consider this statement from Sean in a recent newsletter piece to keep perspective....and they will probably qualify the test results in a similar way in the PR:
But again we like to caution that first well in Yamalick that we drilled was drilled as an exploration well. The fracking that we did was very small fracks at the time, just to see if we could actually recover the gas. We really hadn't expected the rates that we got and that's why we had to stop testing at the time and get the right equipment out there. So we fracked maybe less than half of the net pay in the well and then we had that aggregate flow rate, so once you get doing this in more of a production mode, we do see potential to get much higher rates there.
http://files.constantcontact.com/f5fd2524701/19f1abc7-6ff0-46ef-9341-45f7c7bd7d37.pdf
Regarding Baillie Gifford, they only bought half of the $60 million private placement, or 5.2 million shares announced March 1st and has since more than doubled their position on the open market at a discount to the private placement pricing as per the alternative monthly reports filed on SEDAR in April and June. The June report stated:
Since the last report filed for March 2018, the number of Common Shares held by certain funds and discretionary accounts over which Baillie Gifford has direction and control increased by 2,688,000 Common Shares from the 10,535,700 Common Shares previously reported. As a result, Baillie Gifford’s security holding percentage increased by 2.85% from approximately 12.59% to approximately 15.44%.
FCCG: Looks like the market likes it.
FCCG is getting the Series A Fixed Rate Cumulative Preferred Stock for the same price as offered on June 14th....
Looks like they are getting closer to a merger.....did I share the interview here with Andy Wiederhorn where he contemplated that a merger may happen next year?
It seem likely the marijuana media frenzy could find it's way to Nemus as this initiative with Dr. Schubert develops:
https://www.cnbc.com/2017/03/09/major-buzz-kill-for-alzheimers-research-government-view-of-marijuana.html
There's a smart accumulator at work....when the short-term minded are ready to give some up, they come in and snatch up everything on the bid up to $0.30s....almost as if they take their cues off of "Att_for_life"'s ADD style posts.
VLE.to: From what I read the leading opposition candidate, Muharrem Ince, is more free market and EU friendly than Erdogan, but I agree that Erdogan does not seem to have any intention to nationalize companies or assets as it stands now either:
https://en.mehrnews.com/news/134778/We-would-immediately-establish-diplomatic-ties-with-Syria-Muharrem
VLE.to: I've been adding near the support level here. I expect it to firm up after the Turkish election, which will at least provide a more certain picture of the future, of which the worst case seems would be a continuation of Erdegron....which aside from the dramatic news headline...I don't think it would actually be detrimental to VLE and partner Statoil.
Also, looking forward to the drilling and testing to resume soon....seems they may have drilled their first well into a tighter part of the formation to demonstrate continuity, then the next one is going into an area where seismic shows a great degree of natural fracturing.
Their May 29th Investor Day presentation has been out for a while, but I didn't see anyone mention it here. Page 48 shows the seismic interpretation and slide 69/83 makes a very compelling case for the value in their reserves and land position: http://www.valeuraenergy.com/upload/media_element/111/02/valeura-2018-investor-day.pdf
Well thought out posts...."once in a while you get shown the light in the strangest of places if you look at it right".
https://www.salk.edu/news-release/cannabinoids-remove-plaque-forming-alzheimers-proteins-from-brain-cells/
World Cannabis Congress....I've reviewed the agenda, speakers, and sponsors and fail to see any connection to Nemus, or even Emerald....what am I missing?
This is still a low float stock, unless we see Emerald's shares beginning to hit the market, but I think they want to maintain a controlling position for strategic purposes.
It seems like a smart buyer took notice at LD Micro, bought a little, let the nervous-nellies out, and is back on the bid.
The company's June investor presentation on their homepage lays out a clear path to clinical trials for NB1111 with several newsworthy milestones highlighted over the next 12 months....I think the market will take notice as this company takes a smart strategic path to clinical trials for NB1111.....and there's good reason to believe there's other irons in the fire as well.
This is one of the cheapest and highest quality cannabis pharmaceutical stocks on the market. There's been a few months since the financing for the company to plan their next steps....we know they are looking to fine tune their drug delivery platforms and advance some of their candidate molecules into Phase I, they're also seeking big pharma partners to lead the clinical programs....any significant progress on these fronts and these prices will be a distant memory.
VLE.to: Everyone is chicken to invest in Turkey, that's why this discovery is being valued like chopped liver by many, but I think when drilling and testing resumes they're going to put up some numbers that put the Turkey on the table.
I don't think we need dig too deep into the geology, as the D&M Resource Report does a pretty good job of showing the very preliminary exploration work they've done shows the company is sitting on billions of dollars worth of natural gas and condensate already....with some significant upside potnetial which they intend to explore this summer: https://www.newswire.ca/news-releases/valeura-announces-prospective-resources-for-unconventional-basin-centered-gas-prospect-673038843.html
I understand the trepidation about investing in Turkey, Erdogan is a wild card, but even at that, Turkey has no history of ever nationalizing an asset or company. Valeura's partner, Statoil (66% owned by the state of Norway) is the best strategic partner one could imagine for bringing political pressure to assure Turkey acts in the best interest of free markets. Turkey is 99% reliant on foreign natural gas supply and desperately needs this asset to be developed, which could help stabilize their energy supply....and even the value of their currency.....yes, this discovery is really that big. The asset also happens to be smack dab in the middle of some major energy pipeline fairways, so investment to get it to market will be minimal.
I have invested significantly here, I think these slides go a long way to showing the value here:
PROM was the top pick in the contest, but I can't find much information on their platform "owned and ope rated properties". Can anyone point me to some of their "properties" where they offer free premium content in exchange for advertising?
From their 10k: "Owned and Operated Properties. Propel develops and distributes multiple free casual gaming, lifestyle and other content properties. In this method, Propel buys media and advertises these gaming sites and lifestyle content properties on various online destinations, including casual gaming and social media portals. Propel provides its audience with access to its premium gaming and lifestyle content for free and obtains the user’s permission to serve advertising to them while they peruse content on the web. Propel incurs media costs to acquire audiences in this manner."
It's kind of weird to me that they don't mention the actual properties anywhere on their website or filings, I suspect they may be those ad servers that show you the "10 most emberassing wardrobe malfunctions" or "10 most opulent celebrity weddings", or what have you....but just want to see and verify these "properties" for myself.
Just beginning my due diligence, but this feels a little too much like a stock I followed Bobwins into back in the early 2000s @ RagingBull....can't remember the name or ticker now....but they appeared to be profitable and claimed to have all these internet businesses with little verifiable customer traction....turned out that they were completely faking the books and faking out their auditors too for a while....800America.com....that was it....man I don't need to repeat that mistake again!
I don't mean to say Propel is that same level of scammy....kind of just went on a tangent explaining why it's important for me to verify these kind of things first.....but I see Propel has a fairly open Facebook page showing a bustling office and all....looks fairly legit, even if they are just pumping out internet trash....
DAP-u.v/XPLT: XPEL Reports Record First Quarter Revenue Growth of 99.5% to $25.2 Million and EPS of $0.07
Business Wire Business Wire
May 23, 2018
SAN ANTONIO--(BUSINESS WIRE)--
XPEL Technologies Corp. (TSXV: DAP.U), a leading supplier of automotive paint protection and window films, announced results for the first quarter ended March 31, 2018.
First Quarter Highlights:
Revenues increased 99.5% to $25.2 million compared to first quarter 2017; Sequential revenue growth of 24.5% compared to fourth quarter of 2018
Gross margin improved to 29.7% compared to 26.4% in first quarter 2017
Selling, general and administrative expenses decreased to 19.4% as a percentage of revenue
Earnings per share of $0.07 compared to a loss of ($0.002) per share in first quarter 2017
Revenues for the quarter grew 99.5% to $25.2 million. Gross profit as a percentage of sales was 29.7% as compared to 26.4% in the prior quarter. Selling, general and administrative expenses increased to $4.9 million, or 19.4% of revenue, as compared to $3.3 million, or 26.3% of revenue, in the prior year quarter. Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) increased $2.7 million to $3.1 million compared to $0.4 million in the prior year quarter. Net income was $2.0 million or $0.07 per basic and diluted share, compared to a net loss of ($.06) million or a loss of ($0.002) per basic and diluted share in the prior year quarter.
Mr. Ryan Pape, President and Chief Executive Officer of XPEL, commented, “First quarter 2018 is the strongest quarter in our Company’s history, with record revenues reflecting strong demand across all of our product lines. Revenue grew by almost 100% over the first quarter of 2017 and by 25% sequentially, illustrating considerable momentum in our business. We also saw strong improvement in our gross margin percentage as the margin enhancement initiatives we began in Q3 last year have started to take hold.
“We are energized by the tremendous growth achieved in the first quarter and the increased demand for our products and unique services. We remain focused on continuing to drive profitable growth as we expand our presence in both domestic and international markets, capture new customers and grow our market share,” Mr. Pape concluded.
For the Quarter Ended March 31, 2018:
Revenues. Revenues increased approximately $12.6 million to $25.2 million, or 99.5% over the prior year period.
Gross Margin. Gross profit for the quarter grew 124.85% vs prior year quarter and increased as a percentage of sales to 29.7% from 26.4%.
Expenses. Selling, general and administrative expenses increased $1.6 million or 47.7% vs. prior year period but decreased as a percentage of sales to 19.4% of sales from 26.3% of sales in the prior year. This increase was due mainly to increases in personnel, occupancy, sales and marketing and information technology related costs to support the ongoing growth of the business.
EBITDA. EBITDA increased $2.7 million to $3.1 million vs prior year quarter.
Net income. Net income for the quarter increased to $2.0 million versus a loss of $.06 million in the prior year quarter.
Conference Call Information
The Company will host a conference call to discuss the first quarter results today, May 23, 2018, at 11:00 a.m. Eastern Time.
To access the live webcast, please visit the XPEL Technologies website at www.xpel.com/investor.
To participate in the call by phone, dial (877) 407-8033 approximately five minutes prior to the scheduled start time. International callers please dial (201) 689-8033.
A replay of the teleconference will be available until June 23, 2018 and may be accessed by dialing (877) 481-4010. International callers may dial (919) 882-2331. Callers should use conference ID: 28532.
About XPEL Technologies Corp.
XPEL leads the industry in designing, manufacturing and distributing high-performance automotive paint and headlamp protection film technologies. Using XPEL’s proprietary software and materials, our professional design team develops products that deliver the ultimate in vehicle protection, meeting the demands of a broad range of makes and models. With more than 70,000 vehicle-specific applications and a global network of trained installers, XPEL is dedicated to exceeding customer expectations in providing high-quality products, customer service and technical support. XPEL Technologies Corp. (TSXV: DAP.U) is publicly traded on the TSXV Exchange. Visit www.xpel.com for more information.
Biosynthesis is cheaper, faster, and offers better quality control.
Cheaper because less energy inputs and time are needed for biosynthesis, faster life cycle means greater production can be achieved in less time, and quality control means specific compounds can be developed without contamination from other plant-derived contaminants.
That's not to mention that the term "CBD Oil" typically refers to a mixture composed primarily of cannabidiol, but also consisting of several minor cannabinoid constituents like CBC and CBG, which are two canabanoids Nemus indicates are responsible for analgesic affects. These compounds come in trace concentrations in plant material, but can be concentrated and refined more in a biosynthesis process.
Dateline NBC talking about analgesic affects and anti-addictive properties of marijuana.....really seems like it's just a matter of time before Nemus finds itself in the spotlight of this conversation:
https://m.facebook.com/story.php?story_fbid=10156247641241420&id=117112876419
COVALON ANNOUNCES MAJOR SALES BREAKTHROUGH – WINS CONTRACTS WITH AN ESTIMATED VALUE OF $100 MILLION OVER A THREE-YEAR PERIOD
Conference call scheduled for Tuesday May 8th at 9am EDT to discuss the impact of this major transformative event
MISSISSAUGA, Ontario--(BUSINESS WIRE)--May 7, 2018-- Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, has been informed that it has won a series of competitive contracts in the Middle East with an estimated sales value of $100 million over a three-year period.
The series of competitive contracts awarded to Covalon includes the granting of approximately ten categories of products under the Executive Board of Health Ministers’ Council for Gulf Cooperation Council States (called “SGH”), as well as several contracts outside of the SGH in Saudi Arabia and other countries in the region that extend up to three years to supply Covalon’s highly-regarded IV Clear, ColActive Plus, and CovaWound products.
The majority of the contracts have been awarded to Covalon through highly competitive bidding processes that involved the clinical evaluation of each product. The series of winning contracts extend over a period of three years and management anticipates delivery of the products under the contracts to commence by the Company’s fiscal quarter ended December 31st 2018.
As more information becomes available, Covalon will provide further updates on the impact of each of these contract wins.
Brian Pedlar, Covalon’s Chief Executive Officer, commented, “By winning these highly sought-after competitions against some major medical companies, Covalon has proven that it has truly differentiated, life-saving medical technologies.
“These contracts transform Covalon into a significant healthcare player in the vascular access and wound care markets. We anticipate the contracts to deliver approximately $100 million of revenue to Covalonover the contractual periods of up to three years and provide Covalon with a very stable and predictable base of sales on which to continue to build our market presence internationally.
“We competed against very large and highly-respected medical companies for these contracts with our flagship products IV Clear, ColActive Plus, and several products in our CovaWound line. These contracts secure Covalon’s business in the Middle East and allow us to focus on introducing new products into the region as we deliver under these contracts over the next three years.”
Conference Call Scheduled
The Company has scheduled a conference call to be held Tuesday May 8th at 9:00 a.m. EDT to further discuss this major sales breakthrough. To participate in the call please dial:
Local / International: 647-689-4535
North American Toll-Free: 1-833-299-8117
About Covalon
Covalon Technologies Ltd. researches, develops and commercializes new healthcare technologies that help save lives around the world. Covalon's patented technologies, products and services address the advanced healthcare needs of medical device companies, healthcare providers and individual consumers. Covalon's technologies are used to prevent, detect and manage medical conditions in specialty areas such as wound care, tissue repair, infection control, disease management, medical device coatings and biocompatibility. To learn more about Covalon, visit our website at www.covalon.com
That response is intellectually lazy and doesn't even really warrant a response, he's comparing apples to bushel baskets for all I can tell.
He says "they have struggled with distribution domestically and abroad the product is also too expensive… Microbecare technology is better"
First off, has he seen Covalon's growth over the past year or so? I wouldn't call it a strugle, it's more like an inflection point, and Covalon has only just begun to hire sales and marketing people for the US market.
Secondly, the comparison to MicrobeCare really makes no sense based on a quick review of their website, which is apparently more effort than this person put into researching Covalon. Covalon makes advanced wound care products and coatings for implantable medical devices along with the other companies mentioned here, who have also been around for years: http://expressobserver.com/global-medical-device-coatings-market-2018-surmodics-inc-royal-dsm-biocoat-inc-coatings2go-llc-hydromer-inc-73146.html
From a brief review of MicrobeCare, it appears they make antimicrobial coatings for medical EQUIPMENT, like hospital beds and computer periphials. I do not see any evidence they are even involved in wound care products or implantable/interventional medical devices.
FCCG: This interview with CEO, Andy Wiederhorn, goes a long way to validating Maj @GeoInvesting's original investment thesis here:
http://regaresearch.com/2018/05/03/investors-might-have-overlooked-this-juicy-merger-on-fats-menu/
It's actually kind of funny that the author wrote thie piece to discuss how this merger would add value to FAT shares, but fails to mention FCCG trades at nearly a 50% discount to their equity in FAT share holdings. HELLO....anyone happen to notice a ticket for first class is cheaper than coach for this ride?
Given that, it's also kind of funny CEO is reassuring recent FAT IPO investors they will be treated fairly in a merger transaction with FCCG.
Even with FAT shares at a low near $5.70, each FCCG share has about $3.80 per share equity in FAT.
NMUS is steering their development efforts right into that hot spot of abuse deterrent and opiod alternatives to pain managment that Dr. Gupta is talking about too, take note of slide #34 of their March 2018 slide deck (available on bottom of their homepage), their NB2111 program is now targeting "Pain Syndromes" more broadly than their previous "Chemotherapy Induced Neuropathy" target discussed in previous presentations and the development timeline has them ready for a clinical POC study early next year now!
Previously, they had their NB1222 for Chemotherapy Induced Nausea and Vomiting (CINV) was higher priority, but now it is "Prioritization Pending Further Market Analysis"....which I suspect means they are shopping for a partner to fund that now, to allow them to use their funds to pursue the big fish of "Pain Syndromes".
NMUS sure looks cheap relative to competitors when you consider the size of the markets they are going after.
This CNN Dr. Gupta special is amazing! ....Dr. Gupta needs to be shown what NMUS is doing.....so I might be trolling his Twitter feed just a little...
Anyone notice the March update to the slide deck included some new language and a bit more emphasis on NB2111 for "Pain Syndromes" (pages 24 - 27).
I particularly liked these notes on 24:
Potential Alternative For
Opioid Abuse Epidemic
• The overall global pain market is projected to be $35 billion by 2017
......
• Opioid abuse now at epidemic proportions globally
• Government officials and patient advocacy groups are calling for the
exploration of medical cannabinoids as alternatives to opioid-based analgesics
Sanjay Gupta is going to be running marijuanas potential as a substitute for opiates up the flagpole on CNN Sunday evening, while I don't expect NMUS to be mentioned directly, it doesn't take much imagination to see how this could bring a lot more prospective investors and pharma partners over to take a good look at NMUS.
Proprietary biosynthetic pharmaceutical compounds.
Here's a PR a out their intentions to use biosynthesis to more efficiently produce their target compounds:
Nemus Bioscience Announces License of Biosynthetic Technology from Teewinot Life Sciences to Manufacture its Proprietary Cannabinoid Molecules
12/20/2016
COSTA MESA, CA / ACCESSWIRE / December 20, 2016 / NEMUS Bioscience, Inc. (NMUS) announced it has signed a definitive license agreement for rights to Teewinot Life Sciences Corp.'s patented biosynthetic technology to produce NEMUS' proprietary cannabinoid molecules.
"Nemus is anticipating an era of hypergrowth in the pharmaceuticalized cannabinoid space and we believe that the biosynthetic technology that Teewinot has developed fits with our industry-disruptive approach to this therapeutic market," commented Brian Murphy, M.D., M.B.A., CEO and Chief Medical Officer of Nemus. "We believe that the use of standard cannabinoid molecules like tetrahydrocannabinol (THC) and cannabidiol (CBD) can be improved upon using re-engineered proprietary forms of the molecules to enhance physicochemical characteristics, resulting in improved activity and safety in a business model not solely dependent on orphan drug applications. We anticipate that the biosynthetic technology being advanced by Teewinot will provide API that is more cost-effective to produce than pure chemical synthesis or deriving the molecules from plants."
Jeffrey Korentur, CEO of Teewinot Life Sciences Corporation, stated, "Our wholly owned subsidiary, Full Spectrum Laboratories, Ltd., is working to bring disruptive technologies to the area of cannabinoid manufacturing. The Teewinot team is working with Albany Molecular Research, Inc. (NASDAQ:AMRI) to advance the scale-up of biosynthetically produced products, and AMRI already has a relationship with Nemus related to API manufacturing. Our patented biocatalytic production methods and equipment offer the potential to improve not only purity and variety, but also the speed and cost of producing cannabinoid molecules over traditional botanical extraction or chemical synthesis methods."
"Nemus looks forward to the versatility of biosynthetic manufacturing to help us manufacture other cannabinoids we are currently studying for indications such as pain management and anti-infectives, especially related to resistant bacterial infections like methicillin-resistant Staphylococcus aureus (MRSA)," reported Dr. Murphy.
Sanjay Gupta has a special this Sunday night at 8:00 on CNN about marijuana's potential to help stem the opiate epidemic:
https://chicago.suntimes.com/cannabis/sanjay-gupta-jeff-sessions-medical-marijuana-cannabis-pot/
There is going to be a lot of peoe looking at this issue and NMUS should be right in the center of this conversation, lets follow the news releases, call in to shows, and do everything else we can to be sure the investment community and public at large get a look at NB2111:
http://www.nemusbioscience.com/investor-relations/investor-news/investor-news-details/2017/Nemus-Bioscience-Announces-Presentation-of-NB2111-Analgesic-and-Anti-Addiction-Data-at-NIH-Sponsored-Cannabinoid-Conference/default.aspx
http://www.nemusbioscience.com/investor-relations/investor-news/investor-news-details/2017/Nemus-Bioscience-Announces-NB2111-Pain-and-Anti-Addiction-Data-Accepted-for-Presentation-at-Upcoming-Society-of-Neuroscience-Meeting/default.aspx
Yes, this article also menions AXIM and NTEC....feel free to compare platforms and valuations:
https://www.reuters.com/article/us-marijuana-fda/high-hopes-ride-on-marijuana-painkillers-amid-opioid-crisis-idUSKBN19E1NU
That "interview" was actually more of a mini-panel discussion of 420 weed day and the big picture of legalization, Avtar didn't even get to mention Emerald's business, but did talk pharmaceutical development prospects a little based on GW, then Payne responded by talking about increases in impaired driving in Colorade???? Payne's interview skills and lack of framiliarity on the subject prevented much substantive conversation....and with the stupid joke suggesting Avtar and the other guest were going to get stoned afterwards, proved himself to be a mindless mouthpiece for establishment conservative political positions.
Emerald's Executive Chairman to be Interviewed on Fox Business News
Hello,
We thought you might like to know that Emerald’s Executive Chairman, Avtar Dhillon, MD, will be interviewed today on Charles Payne’s Money Show running from 6 – 7 pm ET on Fox Business News.
Thanks Monolith, great discussion with the CEO, I would like to make it a sticky post but the post needs to be <48 hours old. Please repost so I can stick it to the top of the board.
Agreed, NMUS trades at a fraction of the value of CBIS, IN.to, MJNA, and LXRP....all of which are also pre-clinical, pre-revenue companies with debatable drug candidates and credibility in pharmaceutical development experience. I don't see any good reason why Nemus trades at less than half the average valuation of the aforementioned companies. On a relative valuation basis, I think it deserves to be valued above the average of those other companies valuations....being affiliated with the only US approved research agency has to be worth something more.
I also agree there should be more news coming on the pipeline update, capital restructuring, and plan to uplist.
I have a hard time believing Emerald would make such a drastic change in direction from January 19th when their CEO said: Dr. Avtar Dhillon, CEO and Chairman of Emerald’s Board of Directors. “We greatly value the intellectual capital and discovery capacity of the University of Mississippi, with which Nemus has an exclusive agreement for novel cannabinoid technologies. We will work to support the business and developmental vision of our CEO, Dr. Murphy, across a spectrum of medical indications of unmet need. The Emerald Board believes that Nemus presents a significant value proposition for investors and we look forward to advancing its pipeline into clinical development.”
Further, I don't think Emerald would have placed board members if their intent was a quick flip of their shares......and likewise, I don't think Nemus was so desperate that would have turned over control of their company right off the bat like they did if there wasn't some strategic plan and purpose of giving Emerald a majority position.
That being said, wouldn't they need to register their shares for strategic acquisition and/or mergers to? Emerald Health Sciences, Inc. (EHS) is the current owner of the stake in NMUS, but they are bringing their daughter company, Emerald Health Pharmaceuticals (EHP) public through a Reg A+ IPO:
https://www.newcannabisventures.com/emerald-health-pharma-files-for-50-million-reg-a-ipo/
Would this registration be needed to transfer the shares to EHP, or affect a share swap or some other transaction to combine the businesses if that was in their intent?
Also, I'm not a securities lawyer so take this with a grain of salt, but the company filed 3, S-1 Registrations in January, March, and November of last year with the November filing addressing some of the preferred shares that were bought by Emerald. Aren't they required to keep their S-1's current based on any changes and since Emerald bought some of the preferred stock discussed in the November S-1, so I think they may have been obligated to update it in a reasonable time period as a matter of procedure.
Disclaimer: This situation and this post is all very speculative, investors should take adequate caution and base their own investment decisions on their own research and not invest more than they are willing to lose.
It's standard procedure that newly issued shares, like the shares issued to Emerald Health Sciences (EHS) through the bridge loan and private placement, need to be registered for resale with the SEC in a registration statement like the S-1 that was just filed. This filing does not necessarily mean the shares will be sold, but it does mean that they will be eligible for resale. Read page 6 of the S-1:
Private Placement of Common Stock and Warrants and Shares Issued Upon Conversion of Promissory Note
On January 19, 2018 and February 16, 2018, we issued and sold an aggregate of 32,500,000 shares of our common stock and warrants to purchase 44,200,000 shares of our common stock for aggregate gross proceeds of $3,250,000. We will not receive any proceeds from the sale of shares sold by the selling stockholders. However, we will receive proceeds of $0.10 per share upon the exercise of the warrants for cash. On December 28, 2017, we entered into a secured convertible promissory note pursuant to which Emerald Health Sciences Inc. (“Emerald”) agreed to loan to us up to $900,000. We received $500,000 on December 28, 2017 and the remaining $400,000 on January 19, 2018, at which time the secured convertible promissory note was converted into 9,000,000 shares of common stock at a conversion price of $0.10 per share of common stock
As part of the terms of the Agreement, we entered into a registration rights agreement pursuant to which we agreed to file a registration statement to register for resale the shares of common stock and the shares of common stock underlying the warrants sold in the private placement and issued upon conversion of the secured convertible promissory note. We agreed to use our best efforts to keep the registration statement effective under the Securities Act until the earlier of (i) the date as of which the purchasers may sell all of their shares without restriction or limitation pursuant to Rule 144 and without the requirement to be in compliance with Rule 144(c)(1) or (ii) the date on which the selling stockholders have sold all of the shares covered by the registration statement. We are filing this Registration Statement in order to fulfill our obligation under this registration rights agreement.
Expanding product line, expanding geographic reach, expanding sales and marketing efforts....and the number of shares issued is staying firm at under 22 million. I'm glad to sit and wait for this company's expansion plans to continie to bear fruit.
This is an investment grade microcap company, unlike that other company we are in that just gave away 67% ownership at a discount to market at $0.10, which isn't even enoigh money for them to advance one of their drug candidates through Phase I..
..that is a gamble.
The 2/13 investor presentation shows "144M 100% fully converted", but then shows 27.6M Warrants outstanding......so are the warrants included in that fully converted number? Also, NMUS didn't announce the increase in the private placement until 2/16, so not sure if that's included. Waiting for IR to clarify exactly where we stand now....will update when he gets back to me.
COV was definitely ahead of itself based on what was/is publicly known, but I think this company is like an iceberg with a lot of technology hidden below the surface, or "in the lab" as Brian likes to say, so I only parted with a little during that run to $8 as well as I have a long-term holding here I believe could be worth much more if the company signs a licensing agreement for their coating technology or announces advancement of one of their other technologies we may not even know exists.
As far as sales growth goes, Brian mentioned the possibility of expanding the number of SKUs under the Saudi contracts. The company has also been making investments in the UK and recently got CovaWound products added to the Scottish Drug Tariff program in February 2018:
http://www.isdscotland.org/Health-Topics/Prescribing-and-Medicines/Scottish-Drug-Tariff/Amendments/Docs/2018/2018-02-SDT-AMD-v3.pdf?05:34:36
I also just found their Iranian distributor has a nice informative web presence:
http://m-s-f.ir/%D9%85%D9%82%D8%A7%D9%84%D8%A7%D8%AA-%D8%A7%D9%86%DA%AF%D9%84%DB%8C%D8%B3%DB%8C/?lang=en
It doesn't take much imagination to see there's still lots of room for growth here, it's just a matter of whether payors will be willing to pay for higher quality products.
I can't believe no one else responded to this part of link you posted:
The fundraising still has about $4.42 million more and is not closed yet. We have to wait more to see if the offering will be fully taken.
If this was true, I was either going to be as excited as a kid in a candy store (if they allowed me to participate), or angry as hell (if someone other than Emerald Health Sciences was getting shares on these terms).
I called every number I could find for the company and finally Adam Holdsworth from the IR firm called me back, he assured me this funding round is now closed and was only open to Emerald Health Sciences.....so much for my hopes of having found the deal of a lifetime.
Matt, this is definitely not my typical low OS, low float kind of stock.
This 2/12 presentation showed their OS @ 144 million, accounting for full conversion of preferred shares....and I am uncertain if that accounts for their recent PP:
https://backend.otcmarkets.com/otcapi/company/sec-filings/12544571/content/html#NEMUS_EX991_HTM
I like their pipeline, I like the management teams experience at major biotech/pharma companies, but the value here is dubious....it looks like a value relative to most other marijuana stocks....but that's about it.
I have a starter position and am watching curiously what exactly their "recapitalization plan" is.....
OT: I've heard peoe called cheerleaders on message boards before, but you take it to new lengths....
No, EMHTF is a daughter company of Emerald Health Sciences. EMHTF is the medical and recreational marijuana grower and supplier four d at this URL offering these products:
https://www.emerald.care/products/
They may also patent tecnologies and new botanical compounds that could be licensed to their pharmaceutical or Bioceuticals businesses, but they are primarily engaged in selling dried cannabis, extracts, and oils.
Yes, but Emerald Health Pharmaceuticals is a sister company to Emerald Health Theraputics (EMHTF), they are both daughter companies of Emerald Health Sciences. That is the reason the EMHTF ticker was not mentioned in that PR.
The parent company, Emerald Health Sciences recent acquisition of a majority of the shares of Nemus Biosciences (NMUS) is possibly more relevant to their Pharmaceuticals business than EMHTF, given this management teams past history of using a reverse merger with T-Bird Pharma to form EMHTF.
Newguy49, I can see the cause of confusion between subsidiaries as Chris Wagner, EMHTF's CEO has been discussing "new products, protected products, new multi-billion dollar markets...." and "applying a new toolbox of bioengineering, randomized control trials, etc." to marijuana. Here is an interesting candid interview with him where he discusses the future for product development initiatives.....and it is a bit unclear whether all of this would actually fit under the "Botanicals" and/or "Theraputics" umbrellla of EMHTF: